Mitsuhiro Nishihara

1.1k total citations
29 papers, 900 citations indexed

About

Mitsuhiro Nishihara is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, Mitsuhiro Nishihara has authored 29 papers receiving a total of 900 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 9 papers in Pharmacology and 7 papers in Oncology. Recurrent topics in Mitsuhiro Nishihara's work include Pharmacogenetics and Drug Metabolism (9 papers), Drug Transport and Resistance Mechanisms (7 papers) and Metabolism and Genetic Disorders (4 papers). Mitsuhiro Nishihara is often cited by papers focused on Pharmacogenetics and Drug Metabolism (9 papers), Drug Transport and Resistance Mechanisms (7 papers) and Metabolism and Genetic Disorders (4 papers). Mitsuhiro Nishihara collaborates with scholars based in Japan, United States and Spain. Mitsuhiro Nishihara's co-authors include Y. Koga, Hiroyuki Morii, Masayo Akagawa-Matsushita, Nobuhito Sone, Tatsuo Kurihara, Nobuyoshi Esaki, Tomomi Fujii, Yasuo Hata, Tamao Hisano and Hideo Akutsu and has published in prestigious journals such as Journal of Biological Chemistry, Applied and Environmental Microbiology and Neurology.

In The Last Decade

Mitsuhiro Nishihara

28 papers receiving 859 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mitsuhiro Nishihara Japan 14 555 158 126 125 93 29 900
Y. Koga Japan 13 534 1.0× 228 1.4× 81 0.6× 221 1.8× 100 1.1× 19 849
Gerhard Fiala Germany 8 861 1.6× 255 1.6× 306 2.4× 435 3.5× 49 0.5× 9 1.4k
Masateru Nishihara Japan 19 778 1.4× 188 1.2× 92 0.7× 186 1.5× 18 0.2× 41 1.1k
Shuisong Ni United States 17 423 0.8× 85 0.5× 103 0.8× 161 1.3× 15 0.2× 47 795
Eli K. Moore United States 11 202 0.4× 77 0.5× 25 0.2× 190 1.5× 37 0.4× 25 500
Ioannis Papapostolou Greece 18 380 0.7× 23 0.1× 56 0.4× 71 0.6× 29 0.3× 32 1.1k
R. Pesch Germany 9 1.0k 1.8× 41 0.3× 62 0.5× 168 1.3× 6 0.1× 15 1.7k
Chad R. Weisbrod United States 26 895 1.6× 33 0.2× 130 1.0× 106 0.8× 7 0.1× 47 1.8k
Uladzimir Barayeu Germany 15 402 0.7× 52 0.3× 36 0.3× 49 0.4× 8 0.1× 21 889
Rong Hong Kong 13 224 0.4× 51 0.3× 36 0.3× 63 0.5× 9 0.1× 160 771

Countries citing papers authored by Mitsuhiro Nishihara

Since Specialization
Citations

This map shows the geographic impact of Mitsuhiro Nishihara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitsuhiro Nishihara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitsuhiro Nishihara more than expected).

Fields of papers citing papers by Mitsuhiro Nishihara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitsuhiro Nishihara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitsuhiro Nishihara. The network helps show where Mitsuhiro Nishihara may publish in the future.

Co-authorship network of co-authors of Mitsuhiro Nishihara

This figure shows the co-authorship network connecting the top 25 collaborators of Mitsuhiro Nishihara. A scholar is included among the top collaborators of Mitsuhiro Nishihara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitsuhiro Nishihara. Mitsuhiro Nishihara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cohen, Lawrence H., T. Eric Ballard, Mitsuhiro Nishihara, et al.. (2024). Soticlestat in Vitro Metabolism and Drug-drug Interactions: Comprehensive Investigations Display Minimal Notable Interactions (P9-1.012). Neurology. 102(7_supplement_1). 3 indexed citations
2.
Mukker, Jatinder Kaur, George E. Dukes, Cristina Almansa, et al.. (2022). The pharmacokinetics of oral trazpiroben (TAK‐906) after organic anion transporting polypeptide 1B1/1B3 inhibition: A phase I, randomized study. Clinical and Translational Science. 15(6). 1532–1543. 6 indexed citations
3.
Nishihara, Mitsuhiro. (2019). Inhibitory Effect of Vonoprazan on the Metabolism of [14C]Prasugrel in Human Liver Microsomes. European Journal of Drug Metabolism and Pharmacokinetics. 44(5). 713–717. 3 indexed citations
4.
Matsushita, K, Koichi Suzuki, Mitsuhiro Nishihara, et al.. (2019). Interaction between phenytoin and enteral nutrients and its influence on gastrointestinal absorption.. PubMed. 74(9). 559–562. 5 indexed citations
5.
Nishihara, Mitsuhiro, Hitomi Yamasaki, Richard Czerniak, & Helen Jenkins. (2018). In Vitro Assessment of Potential for CYP-Inhibition-Based Drug–Drug Interaction Between Vonoprazan and Clopidogrel. European Journal of Drug Metabolism and Pharmacokinetics. 44(2). 217–227. 15 indexed citations
6.
Nishihara, Mitsuhiro, et al.. (2018). Differences in nonclinical pharmacokinetics between species and prediction of human pharmacokinetics of TAK‐272 (SCO‐272), a novel orally active renin inhibitor. Biopharmaceutics & Drug Disposition. 39(3). 175–183. 3 indexed citations
7.
Nishihara, Mitsuhiro, et al.. (2017). Long-Term Stability of Cryopreserved Human Hepatocytes: Evaluation of Phase I and II Drug-Metabolizing Enzyme Activities and CYP3A4/5 Induction for More than a Decade. Drug Metabolism and Disposition. 45(7). 734–736. 6 indexed citations
9.
Scott, Graham, et al.. (2012). The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent. European Journal of Clinical Pharmacology. 69(3). 423–430. 14 indexed citations
10.
Ohashi, Tomohiro, Yuya Oguro, Toshio Tanaka, et al.. (2012). Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: Modification of the core skeleton for improved solubility. Bioorganic & Medicinal Chemistry. 20(18). 5507–5517. 60 indexed citations
11.
Nishihara, Mitsuhiro, et al.. (2011). An Unusual Metabolic Pathway of Sipoglitazar, a Novel Antidiabetic Agent: Cytochrome P450-Catalyzed Oxidation of Sipoglitazar Acyl Glucuronide. Drug Metabolism and Disposition. 40(2). 249–258. 10 indexed citations
12.
Nishihara, Mitsuhiro, Hidenori Kamiguchi, Junzo Takahashi, et al.. (2011). Metabolic Fate of Sipoglitazar a Novel Oral PPAR Agonist with Activities for PPAR-γ, -α and -δ, in Rats and Monkeys and Comparison with Humans In Vitro. Drug Metabolism and Pharmacokinetics. 27(2). 223–231. 5 indexed citations
14.
Hata, Yasuo, Tomomi Fujii, Tamao Hisano, et al.. (1998). Crystal Structures of Reaction Intermediates ofl-2-Haloacid Dehalogenase and Implications for the Reaction Mechanism. Journal of Biological Chemistry. 273(24). 15035–15044. 91 indexed citations
16.
Kurihara, Tatsuo, Masaru Miyagi, Susumu Tsunasawa, et al.. (1997). Paracatalytic Inactivation of L-2-Haloacid Dehalogenase from Pseudomonas sp. YL by Hydroxylamine. Journal of Biological Chemistry. 272(6). 3363–3368. 26 indexed citations
18.
Koga, Y., Mitsuhiro Nishihara, Hiroyuki Morii, & Masayo Akagawa-Matsushita. (1993). Ether polar lipids of methanogenic bacteria: structures, comparative aspects, and biosyntheses. Microbiological Reviews. 57(1). 164–182. 254 indexed citations
19.
Nishihara, Mitsuhiro, et al.. (1992). Archaea contain a novel diether phosphoglycolipid with a polar head group identical to the conserved core of eucaryal glycosyl phosphatidylinositol.. Journal of Biological Chemistry. 267(18). 12432–12435. 35 indexed citations
20.
Morii, Hiroyuki, Mitsuhiro Nishihara, Mami Ohga, & Y. Koga. (1988). A diphytanyl ether analog of phosphatidylserine from a methanogenic bacterium, Methanobrevibacter arboriphilus.. Journal of Lipid Research. 27(7). 724–730. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026